CSA MEDICAL, INC.

CSA Medical, Inc. is a medical device company focused on developing spray cryotherapy solutions for interventional pulmonary therapies. The company's flagship product, RejuvenAir® System, is an investigational cryosurgical device designed to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis by applying metered doses of liquid nitrogen at −196°C to damaged airway tissue. The technology targets the underlying cause of chronic bronchitis—dysfunctional cilia and excessive mucus production—by selectively destroying diseased cells while preserving the extracellular matrix, enabling regeneration of healthy airway tissue with minimal scarring. The RejuvenAir System is delivered through a minimally invasive bronchoscopic procedure, typically performed on an outpatient or same-day basis. The company is advancing the device through the SPRAY-CB pivotal clinical trial, a multi-center interventional pulmonology study across leading academic medical centers nationwide. In January 2026, CSA Medical submitted a PMA (Premarket Approval) application to the FDA following positive results from SPRAY-CB, which met its primary endpoint and multiple secondary endpoints with statistical significance. The company serves interventional pulmonology specialists and pulmonary care centers. CSA Medical is based in Lexington, Massachusetts, and maintains an active clinical development and regulatory strategy targeting the large COPD patient population (estimated 9 million Americans with chronic bronchitis).